Catheter Related Bloodstream Infections Market By Type, By Route Of Administration, By Source of Infection/Causative Agents, By Distribution Channel and Geography
Catheter-Related Bloodstream Infections (CRBSIs) Market size was valued at US$ 1.4 billion in 2022 and is poised to grow at a significant CAGR of 5.1% during 2023-2029. The global market is predicted to be driven by an increase in the prevalence of bloodstream infections. According to a study in the journal Continuing Education in Anaesthesia, Critical Care & Pain, catheter-related bloodstream infections happen in about 3% of catheterizations, although they can happen up to 16% of the time. Inaccurate diagnoses have serious consequences, including procedure difficulties that raise morbidity and mortality. Therefore, it is crucial to identify catheter-related bloodstream infections accurately. Moreover, the risk of CRBSI is elevated by hospital-acquired infections. According to the International Journal of Critical Illness and Injury Science, 10 to 20 percent of hospital-acquired infections in the United Kingdom are caused by CRBSI. The infrastructure for health care is being modernized by governments in developing nations, which is anticipated to expand access to healthcare. Additionally, healthcare-associated infections are a significant problem in underdeveloped countries. Therefore, the global market is presented with a huge potential due to the rise in demand for the items brought on by the patient population growth.
Study Period
2024-2030Base Year
2023CAGR
3.5%Largest Market
Asia-PacificFastest Growing Market
North America
The patient is more likely to develop CRBSI if they have immunosuppression, whether it is absolute (like that seen in the critically ill) or relative (like that found in diseases of the blood). The rate of CRBSI is also influenced by the microbiological environment, with higher rates in the intensive care unit than in the outpatient setting. The injection of TPN, frequent catheter access, and improper aseptic procedures are risk factors for CRBSI. The increasing risk of CRBSI is driving the market worldwide. On the other hand, regulations related to culture media and micro-organisms in laboratories restrain the market.
The Catheter-Related Bloodstream Infections (CRBSIs) market in North America are likely to hold a significant revenue share in 2021, and, in the following years, it is predicted to increase rapidly. Due to its well-established health care infrastructure, North America is anticipated to have a significant share of the global market for catheter-related bloodstream infections over the forecast period. From 2020 to 2030, Europe is predicted to be the second-largest market. Due to the rise in hospital-acquired conditions, the catheter-related bloodstream infections market in the Asia Pacific is anticipated to expand quickly over the projected period. According to the Department of Communicable Disease of the World Health Organization, developing countries have a 2 to 20-fold higher risk of healthcare-associated infections than industrialized nations.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2022 |
US$ 1.4 billion |
|
Market CAGR |
3.5% |
|
By Type |
|
|
By Administration |
|
|
By Source Of Infection |
|
Download Free Sample Report
The catheter-related bloodstream infections market is projected to expand at a CAGR of 5.1% during the forecast period
CorMedix, Inc., Geistlich Pharma, TauroPharm GmbH, Fresenius Medical Care, Citius Pharmaceuticals
North America is the fastest-growing region for catheter-related bloodstream infections market
| 1.Executive Summary |
| 2.Global Catheter Related Bloodstream Infections Market Introduction |
| 2.1.Global Catheter Related Bloodstream Infections Market - Taxonomy |
| 2.2.Global Catheter Related Bloodstream Infections Market - Definitions |
| 2.2.1.Type |
| 2.2.2.Administration |
| 2.2.3. Source Of Infection |
| 2.2.4.Region |
| 3.Global Catheter Related Bloodstream Infections Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Catheter Related Bloodstream Infections Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Catheter Related Bloodstream Infections Market By Type , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Non-antibiotic |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Antibiotic |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Others |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6.Global Catheter Related Bloodstream Infections Market By Administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Oral |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Intravenous |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 7.Global Catheter Related Bloodstream Infections Market By Source Of Infection, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Staphylococcus aureus |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. aeruginsa |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Acinetobacter baumannii |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Coli |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Pneuminiae |
| 7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 7.6. Candida Sp. |
| 7.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.6.3. Market Opportunity Analysis |
| 7.7. Others |
| 7.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.7.3. Market Opportunity Analysis |
| 8.Global Catheter Related Bloodstream Infections Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Catheter Related Bloodstream Infections Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Non-antibiotic |
| 9.1.2.Antibiotic |
| 9.1.3.Others |
| 9.2. Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Oral |
| 9.2.2.Intravenous |
| 9.3. Source Of Infection Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Staphylococcus aureus |
| 9.3.2.aeruginsa |
| 9.3.3.Acinetobacter baumannii |
| 9.3.4.Coli |
| 9.3.5.Pneuminiae |
| 9.3.6.Candida Sp. |
| 9.3.7.Others |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Catheter Related Bloodstream Infections Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Non-antibiotic |
| 10.1.2.Antibiotic |
| 10.1.3.Others |
| 10.2. Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Oral |
| 10.2.2.Intravenous |
| 10.3. Source Of Infection Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Staphylococcus aureus |
| 10.3.2.aeruginsa |
| 10.3.3.Acinetobacter baumannii |
| 10.3.4.Coli |
| 10.3.5.Pneuminiae |
| 10.3.6.Candida Sp. |
| 10.3.7.Others |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 11.Asia Pacific (APAC) Catheter Related Bloodstream Infections Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Non-antibiotic |
| 11.1.2.Antibiotic |
| 11.1.3.Others |
| 11.2. Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Oral |
| 11.2.2.Intravenous |
| 11.3. Source Of Infection Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Staphylococcus aureus |
| 11.3.2.aeruginsa |
| 11.3.3.Acinetobacter baumannii |
| 11.3.4.Coli |
| 11.3.5.Pneuminiae |
| 11.3.6.Candida Sp. |
| 11.3.7.Others |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Catheter Related Bloodstream Infections Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Non-antibiotic |
| 12.1.2.Antibiotic |
| 12.1.3.Others |
| 12.2. Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Oral |
| 12.2.2.Intravenous |
| 12.3. Source Of Infection Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Staphylococcus aureus |
| 12.3.2.aeruginsa |
| 12.3.3.Acinetobacter baumannii |
| 12.3.4.Coli |
| 12.3.5.Pneuminiae |
| 12.3.6.Candida Sp. |
| 12.3.7.Others |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Catheter Related Bloodstream Infections Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Non-antibiotic |
| 13.1.2.Antibiotic |
| 13.1.3.Others |
| 13.2. Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Oral |
| 13.2.2.Intravenous |
| 13.3. Source Of Infection Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Staphylococcus aureus |
| 13.3.2.aeruginsa |
| 13.3.3.Acinetobacter baumannii |
| 13.3.4.Coli |
| 13.3.5.Pneuminiae |
| 13.3.6.Candida Sp. |
| 13.3.7.Others |
| 13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Merck Sharp |
| 14.2.2.Dohme Corp |
| 14.2.3.CorMedix, Inc. |
| 14.2.4.Geistlich Pharma |
| 14.2.5.TauroPharm GmbH |
| 14.2.6.Fresenius Medical Care |
| 14.2.7.Citius Pharmaceuticals |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Free Sample
